Evaluate Safety and Immunogenicity of a Vero Cell-Derived JE Vaccine in 9-24 Months of Age Children in Vietnam (JECEVAX-3)
Evaluate the Safety and Immunogenicity of a Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine (JECEVAX) Produced by VABIOTECH (Vietnam) in Vietnamese Children Aged 9-24 Months
Sponsor: Ministry of Health, Vietnam
A PHASE3 clinical study on Japanese Encephalitis, this trial is completed. The trial is conducted by Ministry of Health, Vietnam and has accumulated 9 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Nov 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Oct 2018 — Nov 2018 [monthly]
Completed PHASE3
Status: Recruiting → Completed
-
Jul 2018 — Oct 2018 [monthly]
Recruiting PHASE3
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE3
-
Oct 2017 — Jun 2018 [monthly]
Recruiting PHASE3
First recorded
Sep 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ministry of Health, Vietnam
- Ministry of Science and Technology, Vietnam
- National Institute of Hygiene and Epidemiology, Vietnam
For direct contact, visit the study record on ClinicalTrials.gov .